BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating, Maintains Target Price $2.05

Moomoo NewsJan 6 06:34 ET · Ratings

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswireJan 2 08:00 ET

Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt

MT NewswiresDec 18, 2024 08:34 ET

Express News | Esperion Strengthens Balance Sheet With Closing of Significant Refinancing Transactions

ReutersDec 18, 2024 07:00 ET

Goldman Sachs Upgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Raises Target Price to $4

Moomoo NewsDec 18, 2024 01:31 ET · Ratings

Cantor Fitzgerald Initiates Esperion Therapeutics(ESPR.US) With Buy Rating, Announces Target Price $8

Moomoo NewsDec 17, 2024 17:31 ET · Ratings